
Ischemic stroke remains one of the most devastating and resource‑intensive emergencies in medicine, with the physical removal of a clot, the current gold-standard care, still leaving more than half of patients with poor outcomes at 90 days. Revalesio is developing a next‑generation, oxygenated saline infusion designed to protect the brain during and after clot removal by stimulating mitochondrial function, reducing reperfusion injury, and limiting the spread of damage to surrounding tissue. Revalesio president Greg Archambeau discusses how the company’s experimental therapy may reshape the trajectory of stroke recovery, shorten hospital stays, and change the economics of stroke centers.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Targeting Visceral Fat with RNA Therapeutics

Engineering T-Cell Engagers for Solid Cancers

Resetting Severe Allergies at Their Cellular Source

Innovating ADCs with Dual Targeting and Smarter Delivery
Free AI-powered recaps of The Bio Report and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.